Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study

Background/AimsOnly moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Japan...

Full description

Bibliographic Details
Main Authors: Chen-Wang Chang, Shu-Chen Wei, Jen-Wei Chou, Tzu-Chi Hsu, Chiao-Hsiung Chuang, Ching-Pin Lin, Wen-Hung Hsu, Hsu-Heng Yen, Jen-Kou Lin, Yi-Jen Fang, Horng-Yuan Wang, Hung-Hsin Lin, Deng Cheng Wu, Yen Hsuan Ni, Cheng-Yi Wang, Jau-Min Wong
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2014-10-01
Series:Intestinal Research
Subjects:
Crohn disease
Adalimumab
Efficacy
Safety
Online Access:http://www.irjournal.org/upload/pdf/ir-12-287.pdf

Internet

http://www.irjournal.org/upload/pdf/ir-12-287.pdf

Similar Items